Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

Merck's Tepmetko (tepotinib) was approved by the FDA last year for both treatment naïve and previously treated METex14 positive NSCLC patients, as was Novartis' Tabrecta (capmatinib), while ...